FULC — Fulcrum Therapeutics Share News
0.000.00%
Last trade - 00:00- $253.21m
- -$80.11m
Brief: Fulcrum Therapeutics Approves Restructuring Plan After Discontinuing Pociredir For Sickle Cell Disease
U.S. STOCKS ON THE MOVE-Hewlett Packard, Alphabet, Fulcrum
U.S. STOCKS ON THE MOVE-Hewlett Packard, Alphabet, Philip Morris
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum plummets over 50% after scrapping lead sickle-cell drug on FDA concerns (updated)
U.S. STOCKS ON THE MOVE-Dollar General, Vera, Amtech Systems
U.S. STOCKS ON THE MOVE-Microchip Technology, Marvell Technology, Generac
Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns
Fulcrum falls after discontinuing sickle cell drug program
U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Alphabet Reports Stake In PayPay And CME Group, Dissolves In Dexcom
Fulcrum Therapeutics Q1 net loss widens on higher expenses
Brief: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Fulcrum Therapeutics reports bigger Q4 net loss
Brief: Fulcrum Therapeutics Announces Positive Results From 20 Mg Dose Cohort Of Phase 1B Pioneer Trial Of Pociredir
Brief: Fulcrum Therapeutics Announces Pricing Of Upsized $175.0 Million Public Offering Of Common Stock And Pre-Funded Warrants